This article is more than 5 years old. Information may no longer be current.

VIDEO: Alimera highlights Iluvien research at ARVO

BySamer Kaber, MD

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

VANCOUVER, British Columbia — Samer Kaba, MD, the new chief medical officer at Alimera Sciences, discusses research regarding Iluvien (fluocinolone acetonide intravitreal implant 0.19 mg), the company’s diabetic macular edema treatment, at the Association for Research in Vision and Ophthalmology meeting.